Introduction
============

Vulvovaginal candidiasis (VVC) is an infectious disease affecting the female genital tract and is caused by *Candida* spp. Of all the VCC cases, 80%--90% are caused by *Candida albicans*, and a minority are caused by *Candida glabrata*, *Candida parapsilosis*, and *Candida tropicalis*.[@b1-idr-11-1893] As one of the most common infectious diseases of the female genital tract, VVC is found worldwide affecting the health of women at all levels of the society.[@b2-idr-11-1893] With the widespread use of corticosteroids, broad-spectrum antibiotics, and immunosuppressants, as well as the emergence of AIDS, VVC is more commonly encountered in clinical practice,[@b3-idr-11-1893],[@b4-idr-11-1893] and the treatment of VVC has become a hot issue.

Antifungal drugs exert their effect by changing the permeability of fungal cell membrane. At present, two groups of antifungal drugs are mainly used to treat VVC: polyene anti-fungal drugs and pyrrole ring antifungal drugs. The former group is represented by amphotericin B. Amphotericin B has a strong antifungal activity and a wide antibacterial spectrum, but it is quite toxic. The latter group includes azoles, such as ketoconazole, fluconazole, and itraconazole. These are also most widely used and have a wide antibacterial spectrum.[@b5-idr-11-1893],[@b6-idr-11-1893]

To evaluate the clinical efficacy of different antifungal drugs in the treatment of VVC and to provide an evidence-based reference for clinical use, we conducted a network meta-analysis based on randomized controlled trials on the efficacy of antifungal drugs in the treatment of VVC.

Methods
=======

Search strategy
---------------

The published studies on the effectiveness of antifungal drugs in the treatment of oral candidiasis (up to April 2018) were retrieved from PubMed, Embase, the Cochrane Library, and [ClinicalTrials.gov](http://ClinicalTrials.gov), with keywords including "Vulvovaginal Candidiases" \[MeSH\] OR "Vulvovaginal Candidiasis" \[MeSH\] OR "Vulvovaginal Moniliases" \[MeSH\] OR "Vul-vovaginal Moniliasis" \[MeSH\] OR "Vaginal Yeast Infections" \[MeSH\] OR "Genital Vulvovaginal Candidiasis" \[MeSH\] OR "Genital Vulvovaginal Candidiases" \[MeSH\] OR "Genital Candidiases" \[MeSH\] OR "Genital Candidiasis" \[MeSH\] OR "Monilial Vaginitides" \[MeSH\] OR "Monilial Vaginitis" \[MeSH\] AND "Antifungal Agents" \[MeSH\] OR "Itraconazole" \[MeSH\] OR "Miconazole" \[MeSH\] OR "Clotrimazole" \[MeSH\] OR "Fluconazole" \[MeSH\] OR "Ketoconazole" \[MeSH\] OR "Econazole" \[MeSH\] OR "Butoconazole" \[MeSH\] OR "Terbinafine" \[MeSH\] OR "Terconazole" \[MeSH\] AND "Randomized Controlled Trials" \[MeSH\] OR "RCT" \[MeSH\].

Inclusion and exclusion criteria
--------------------------------

We included randomized controlled trials written in English, regardless of whether or not specific random allocation methods and blind data hiding scheme are mentioned and the timing of publication. Study subjects were females with typical clinical symptoms and signs of VVC confirmed by mycological examination.

We imported the literature retrieved from the database into EndNote and eliminated duplicates. We screened the titles and abstracts according to the Patients, Interventions, Comparisons and Outcomes principle, and then read the full text of the eligible articles. The data were extracted and evaluated by two reviewers. Any differences in opinion were discussed and resolved by the reviewers. The following data were extracted: first author of the study, publication time, sample size, age, and intervention measures. Quality evaluation was performed using Cochrane risk-of-bias assessment tool.

Statistical analysis
--------------------

We conducted a network meta-analysis (Bayesian approach) which included both direct and indirect evidence in the network. Direct comparison was performed using Stata14.0 software for statistical analysis. The risk of vulvovaginal candidiasis in each group was compared using the OR. Before the combined data were analyzed by meta-analysis, the heterogeneity of each group was tested. If there was no heterogeneity (*P*≥0.05 or *I*^2^≤50%), the combined statistics were calculated by fixed-effect model analysis. If there was significant heterogeneity among the groups (*P*\<0.05 or *I*[@b2-idr-11-1893]\>50%), the source of heterogeneity was analyzed, and a subgroup analysis of the factors leading to heterogeneity was carried out. Indirect comparison was made using R software to draw a mesh diagram. Drugs were ranked based on the surface under the cumulative ranking curve (SUCRA) values. A drug was considered more preferable than another if it had a larger SUCRA value.

Results
=======

Literature search results
-------------------------

A total of 566 studies from Medline, 596 studies from Embase, one study from Cochrane Library, and eight studies from [Clin-icalTrials.gov](http://Clin-icalTrials.gov) were selected. After removing duplicates, 581 studies remained. After reviewing their titles and abstracts, 521 citations were excluded. The remaining 60 citations were assessed in more detail for eligibility by reading the full text. Among them, two were excluded due to lack of relevant outcome measure, 14 were excluded due to insufficient network connections, and three were excluded due to lack of detailed information. Finally, 41 studies were used for the final data synthesis.[@b5-idr-11-1893],[@b7-idr-11-1893]--[@b46-idr-11-1893] The flowchart of literature search is presented in [Figure 1](#f1-idr-11-1893){ref-type="fig"}. The risk of bias of the 41 studies included in this meta-analysis is summarized in [Figure 2](#f2-idr-11-1893){ref-type="fig"}. The characteristics of the included studies are shown in [Table 1](#t1-idr-11-1893){ref-type="table"}. The pattern of evidence within the network is displayed in [Figure 3](#f3-idr-11-1893){ref-type="fig"}.

Results of pairwise meta-analysis
---------------------------------

[Table 2](#t2-idr-11-1893){ref-type="table"} displays the results produced by pairwise meta-analysis. The following drugs appeared to show more efficacy than placebo in the treated patients: fluconazole (OR =6.45, 95% CrI 4.42--9.41), clotrimazole (OR =2.99, 95% CrI 1.61--5.55), miconazole (OR =5.96, 95% CrI 3.17--11.2), itraconazole (OR =2.29, 95% CrI 1.21--4.33), ketoconazole (OR =2.40, 95% CrI 1.55--3.71), butoconazole (OR =1.18, 95% CrI 1.06--1.31), and terconazole (OR =5.60, 95% CrI 2.78--11.3). Moreover, there was no significant heterogeneity among the studies for the above results (*P*-heterogeneity \>0.05 and *I*[@b2-idr-11-1893]\<50%).

Network meta-analysis
---------------------

[Table 3](#t3-idr-11-1893){ref-type="table"} displays the results produced by network meta-analysis. The following nine drugs appeared to show more efficacy than placebo in the treated patients: fluconazole (OR =26.0, 95% CrI 14.0--50.0), clotrimazole (OR =17.0, 95% CrI 8.70--34.0), miconazole (OR =12.0, 95% CrI 6.30--22.0), itra-conazole (OR =14.0, 95% CrI 6.40--32.0), ketoconazole (OR =13.0, 95% CrI 6.10--27.0), econazole (OR =14.0, 95% CrI 5.10--38.0), butoconazole (OR =25.0, 95% CrI 12.0--56.0), terbinafine (OR =5.20, 95% CrI 1.70--35.0), and terconazole (OR =18.0, 95% CrI 7.80--43.0).

The corresponding SUCRA values of the drugs were as follows: placebo (0.5%), fluconazole (91.5%), clotrimazole (61.8%), miconazole (33.8%), itraconazole (50.5%), ketoconazole (42.8%), econazole (46.8%), butoconazole (82.2%), terbinafine (20.9%), and terconazole (65.0%) ([Figure 4](#f4-idr-11-1893){ref-type="fig"}). Incorporating adjuvants particularly fluconazole appeared to be the best strategy for the treatment of oral candidiasis.

Publication bias
----------------

The results of the comparison-adjusted funnel plots did not reveal any evidence of apparent asymmetry ([Figure 5](#f5-idr-11-1893){ref-type="fig"}). No significant publication bias was observed.

Discussion
==========

VVC has a high incidence and recurrence rate, but its pathogenesis is not yet clear.[@b47-idr-11-1893] At present, it is believed that the pathogenesis and recurrence of VVC are related to many factors, such as the increasing resistance of *Candida*, the local immune response of host against *Candida*, and the change of virulence factor of *Candida*.[@b48-idr-11-1893],[@b49-idr-11-1893] Available data show that 75% of women have VVC at least once in their lifetime, and 50% of women with VVC have recurrent infections, with the highest incidence found among women of reproductive age.[@b50-idr-11-1893] VVC is the most common cause of vaginal infections, second only to bacterial vaginitis. *Candida* has a high rate of intravaginal colonization; it can be isolated from the vagina of about 20% of healthy asymptomatic women and 30% of pregnant women.[@b51-idr-11-1893]

*Candida*, as a part of normal flora, can be found on the surface of the skin, digestive tract, and genitourinary tract; however, the mechanism of colonization and pathogenicity of *Candida* are unclear. The pathogens of VVC include *C. albicans*, *C. tropicalis*, *C. parapsilosis*, *Candida krusei*, and *C. glabrata*.[@b52-idr-11-1893] *C. albicans* is the main pathogen of VVC, and accounts for 73.8%--95.0% of all *Candida* spp. isolated from the vagina. The most common non-albicans species is *C. glabrata*, which accounts for 10%--20% of all VVC pathogens.[@b53-idr-11-1893] VVC causes increased leucorrhea, vulva itching, burning pain, urinal pain, and intercourse pain, and seriously affects the physical and mental health of the majority of women. Therefore, there is an urgent need for most suitable drugs for the treatment of VVC.

At present, pyrrole ring drugs are mainly used to treat VVC in clinical practice. Pyrrole ring drugs such as imidazoles and triazoles are related to the inhibition of ergosterol synthesis in fungi and thus destroy the integrity of fungal cell membrane and achieve the antifungal effect.[@b54-idr-11-1893] The most common drugs represented by imidazoles are clotrimazole, ketoconazole, and miconazole. Triazoles are represented by fluconazole and itraconazole. Triazole antifungal drugs have a high bioavailability and strong antifungal effect, and the associated liver toxicity is relatively small.[@b55-idr-11-1893]

This network meta-analysis attempted to analyze the effectiveness of different antifungal drugs in the treatment of VVC and to provide an evidence-based reference for clinical use. Our analysis suggested that antifungal drugs are effective in the treatment of VVC, and fluconazole appeared to be best drug for the treatment of VVC. The American and European guidelines for the treatment of VVC, based on a large number of evidence-based clinical practice, recommended the use of fluconazole (150 mg) for the treatment of moderate-to-severe VVC, which is consistent with our results.

Fluconazole is a triazole antifungal drug that can inhibit or kill fungi by competitively inhibiting the synthesis of ergosterol. It has shown a significant effect in the treatment of deep fungal infections, especially those caused by *C. albicans* and *Cryptococcus neoformans*.[@b56-idr-11-1893] Since it was launched in 1988, fluconazole has been widely used in clinical practice because of its excellent pharmacokinetic properties, such as broad antifungal spectrum, low hepatotoxicity, good oral absorption, high bioavailability, and wide tissue distribution.[@b57-idr-11-1893] Designated by the WHO as the first choice for the treatment of systemic fungal infections, fluconazole is effective for various human and animal fungal infections, such as *Candida* infection (including systemic candidiasis in normal or immune-impaired people and animals), new cryptococcus infection (including intracranial infection), *Malassezia*, *Microsporum*, and *Trichophyton* infections, psoriasis, dermatitis, and rougherosporum (including intracranial infection). The antibacterial activity of fluconazole in vitro was found to be significantly lower than that of ketoconazole, but the antifungal activity of this drug was significantly higher than ketoconazole in vitro.[@b57-idr-11-1893]

This meta-analysis also has some limitations. The results of statistical heterogeneity analysis of the antifungal drugs are limited in randomized controlled trials. In addition, the limited evidence of a dose-dependent association between antifungal drugs and VVC treatment provides limited confi-dence in the study findings. Second, there is no record for a standardized treatment of VVC, which leads to difference in results between the trials; therefore, these results should be carefully interpreted with caution. Third, the study durations were short in these randomized controlled trials and patients included in these trials might be different from patients in the real life. Fourth, these findings may not be generalizable to a specific group of patients because randomized controlled trials tended to exclude participants. Fifth, most of the including studies have not enough detail in their reports, such as the absence of a random allocation method, the implementation of the allocation concealment, or the implementation of the blind law, which leads to existence of varying degrees of bias and risk.

Our findings underscore the notion that antifungal drugs are effective in the treatment of VVC, and flucon-azole appeared to be the best drug for the treatment of VC according to our analysis. However, due to the low quality of the included studies, this conclusion needs to be further confirmed by high-quality research with a large sample.
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![Risk of bias of the included randomized controlled trials (review authors' judgments about each risk-of-bias item for each included study).\
**Note:** +, low risk; −, high risk; ?, unclear risk.](idr-11-1893Fig2){#f2-idr-11-1893}

![Network of randomized controlled trials comparing different antifungal drugs for vulvovaginal candidiasis treatment.\
**Note:** The thickness of the connecting lines represents the number of trials between each comparator, and the size of each node corresponds to the number of subjects who received the same pharmacological agent (sample size) (A: placebo; B: fluconazole; C: clotrimazole; D: miconazole; E: itraconazole; F: ketoconazole; G: econazole; H: butoconazole; I: terbinafine; J: terconazole).](idr-11-1893Fig3){#f3-idr-11-1893}

![Surface under the cumulative ranking curve (SUCRA), expressed as percentages, ranking the therapeutic effects and safety of treatments for vulvovaginal candidiasis.\
**Note:** For efficacy and safety assessment, the pharmacological agent with the highest SUCRA value would be the most efficacious and safe treatment (A: placebo; B: fluconazole; C: clotrimazole; D: miconazole; E: itraconazole; F: ketoconazole; G: econazole; H: butoconazole; I: terbinafine; J: terconazole).](idr-11-1893Fig4){#f4-idr-11-1893}

![Comparison-adjusted funnel plot for the network meta-analysis.\
**Notes:** The red line suggests the null hypothesis that the study-specific effect sizes do not differ from the respective comparison-specific pooled effect estimates. Different colors represent different comparisons (A: placebo; B: fluconazole; C: clotrimazole; D: miconazole; E: itraconazole; F: ketoconazole; G: econazole; H: butoconazole; I: terbinafine; J: terconazole).](idr-11-1893Fig5){#f5-idr-11-1893}

###### 

Characteristics of the included studies

  Study                                           Year   Study location   Treatments                                                                                              
  ----------------------------------------------- ------ ---------------- -------------- ------------ --------- -------------- ------------ --------- -------------- ------------ -------
                                                                                                                                                                                  
  Andersen et al[@b7-idr-11-1893]                 1989   France           Fluconazole    32.1         143/169   Clotrimazole   30.6         131/161                               
  Corić et al[@b8-idr-11-1893]                    2006   Croatia          Fluconazole    NA           41/56     Clotrimazole   NA           9/13                                  
  Costa et al[@b9-idr-11-1893]                    2004   Brazil           Fluconazole    NA           30/38     Itraconazole   NA           27/42                                 
  de Punzio et al[@b10-idr-11-1893]               2003   Italy            Fluconazole    \>18.0       29/38     Itraconazole   \>18.0       21/32                                 
  Fan et al[@b11-idr-11-1893]                     2015   China            Fluconazole    19.0--45.0   241/287   Miconazole     19.0--45.0   220/290                               
  Ferahbas et al[@b12-idr-11-1893]                2006   Turkey           Fluconazole    17.0--54.0   10/15     Itraconazole   17.0--54.0   6/10      Terbinafine    17.0--54.0   4/12
  Li et al[@b13-idr-11-1893]                      2015   China            Fluconazole    29.6         46/58     Terconazole    31.0         47/66                                 
  McClelland et al[@b14-idr-11-1893]              2015   USA              Miconazole     24.0--34.0   75/118    Placebo        23.0--35.0   30/116                                
  Mendling et al[@b15-idr-11-1893]                2004   Germany          Fluconazole    NA           129/161   Clotrimazole   NA           117/154                               
  Mikamo et al[@b16-idr-11-1893]                  1995   Japan            Fluconazole    18.0--54.0   38/50     Clotrimazole   18.0--54.0   30/50                                 
  Mikamo et al[@b5-idr-11-1893]                   1998   Japan            Fluconazole    18.0--55.0   40/50     Itraconazole   17.0--55.0   42/50     Clotrimazole   21.0--54.0   36/50
  O-Prasertsawat and Bourlert[@b17-idr-11-1893]   1995   China            Fluconazole    33.9±8.1     42/53     Clotrimazole   35.3±8.4     40/50                                 
  Osser et al[@b18-idr-11-1893]                   1991   Sweden           Fluconazole    16.0--52.0   100/121   Econazole      18.0--60.0   84/114                                
  Seidman and Skokos[@b19-idr-11-1893]            2005   USA              Fluconazole    37.0±12.2    76/93     Butoconazole   38.8±13.8    56/88                                 
  Sekhavat et al[@b20-idr-11-1893]                2011   Iran             Fluconazole    39.4±13.1    60/72     Clotrimazole   42.2±15.9    49/70                                 
  Sobel et al[@b21-idr-11-1893]                   1995   USA              Fluconazole    18.0--63.0   133/182   Clotrimazole   17.0--64.0   118/176                               
  Sobel et al[@b22-idr-11-1893]                   2004   USA              Fluconazole    NA           160/166   Placebo        NA           23/154                                
  Stein et al[@b23-idr-11-1893]                   1991   USA              Fluconazole    18.0--51.0   80/90     Clotrimazole   18.0--60.0   88/95                                 
  Stein and Mummaw[@b24-idr-11-1893]              1993   USA              Itraconazole   18.0--43.0   35/48     Clotrimazole   18.0--33.0   19/20     Placebo        18.0--39.0   7/22
  Timonen[@b25-idr-11-1893]                       1992   Finland          Fluconazole    \>18.0       50/54     Miconazole     \>18.0       33/47                                 
  Tobin et al[@b26-idr-11-1893]                   1992   UK               Itraconazole   \>18.0       60/92     Clotrimazole   \>18.0       49/88                                 
  van Heusden et al[@b27-idr-11-1893]             1990   Netherlands      Fluconazole    NA           47/49     Miconazole     NA           48/50                                 
  Zhou et al[@b28-idr-11-1893]                    2016   China            Fluconazole    29.9±6.5     61/110    Clotrimazole   29.4±6.2     62/115                                
  Sobel et al[@b42-idr-11-1893]                   1994   USA              Ketoconazole   \>18.0       86/101    Clotrimazole   \>18.0       41/51                                 
  Fong[@b29-idr-11-1893]                          1992   Canada           Itraconazole   18.0--65.0   17/22     Clotrimazole   18.0--65.0   21/22                                 
  Gerhard et al[@b43-idr-11-1893]                 1989   USA              Ketoconazole   \>18.0       27/45     Placebo        \>18.0       21/47                                 
  Kutzer et al[@b46-idr-11-1893]                  1988   UK               Fluconazole    17.0--65.0   63/80     Ketoconazole   17.0--72.0   55/72                                 
  Sobel[@b44-idr-11-1893]                         1986   USA              Ketoconazole   31.9         15/21     Placebo        31.9         6/21                                  
  van der Meijden et al[@b45-idr-11-1893]         1986   Netherlands      Ketoconazole   29.0±6.9     20/23     Miconazole     28.0±7.4     18/19                                 
  Kjaeldgaard[@b58-idr-11-1893]                   1986   USA              Terconazole    \>18.0       18/20     Clotrimazole   \>18.0       17/20                                 
  Puolakka and Tuimala[@b30-idr-11-1893]          1983   Finland          Ketoconazole   16.0--46.0   40/49     Miconazole     18.0--47.0   34/49                                 
  Corson et al[@b31-idr-11-1893]                  1991   USA              Terconazole    18.0--54.0   250/299   Miconazole     18.0--54.0   239/294                               
  Thomason et al[@b32-idr-11-1893]                1990   USA              Terconazole    NA           40/50     Miconazole     NA           34/50     Placebo        NA           7/49
  Brown et al[@b39-idr-11-1893]                   1999   USA              Butoconazole   18.0--65.0   93/101    Miconazole     18.0--65.0   90/104                                
  Ruf and Vitse[@b40-idr-11-1893]                 1990   France           Butoconazole   18.0--56.0   26/29     Econazole      16.0--49.0   24/32                                 
  Kaufman et al[@b37-idr-11-1893]                 1989   USA              Butoconazole   \>18.0       101/115   Miconazole     \>18.0       93/114                                
  Hajman[@b38-idr-11-1893]                        1988   Sweden           Butoconazole   20.0--63.0   28/32     Clotrimazole   19.0--32.0   24/31                                 
  Brown et al[@b33-idr-11-1893]                   1986   USA              Butoconazole   \>18.0       26/32     Miconazole     \>18.0       21/30     Placebo        \>18.0       2/29
  Adamson et al[@b34-idr-11-1893]                 1986   USA              Butoconazole   NA           92/97     Clotrimazole   NA           74/88                                 
  Stettendorf et al[@b35-idr-11-1893]             1982   USA              Clotrimazole   16.0--62.0   45/54     Econazole      16.0--66.0   41/57                                 
  Perera and Seneviratne[@b36-idr-11-1893]        1994   Sri Lanka        Econazole      NA           49/51     Clotrimazole   NA           45/50                                 

###### 

Summary ORs of antifungal drugs and heterogeneity of each direct comparison

  Comparison                     OR (95% CI)         *P*-heterogeneity   *I*^2^   Tau[@b2-idr-11-1893]
  ------------------------------ ------------------- ------------------- -------- ----------------------
                                                                                  
  Fluconazole vs placebo         6.45 (4.42, 9.41)   --                  --       \<0.001
  Clotrimazole vs placebo        2.99 (1.61, 5.55)   --                  --       0.001
  Miconazole vs placebo          5.96 (3.17, 11.2)   0.323               0.0%     \<0.001
  Itraconazole vs placebo        2.29 (1.21, 4.33)   --                  --       0.011
  Ketoconazole vs placebo        2.40 (1.55, 3.71)   0.894               0.0%     \<0.001
  Butoconazole vs placebo        1.18 (1.06, 1.31)   --                  --       \<0.001
  Terconazole vs placebo         5.60 (2.78, 11.3)   --                  --       \<0.001
  Clotrimazole vs fluconazole    0.94 (0.89, 0.99)   0.387               5.7%     0.016
  Miconazole vs fluconazole      0.90 (0.84, 0.96)   0.108               46.7%    0.001
  Itraconazole vs fluconazole    0.92 (0.80, 1.06)   0.408               0.0%     0.245
  Ketoconazole vs fluconazole    0.97 (0.82, 1.15)   --                  --       0.728
  Econazole vs fluconazole       0.89 (0.77, 1.02)   --                  --       0.100
  Butoconazole vs fluconazole    0.78 (0.65, 0.94)   --                  --       0.008
  Terbinafine vs fluconazole     0.50 (0.21, 1.20)   --                  --       0.121
  Terconazole vs fluconazole     0.89 (0.73, 1.10)   --                  --       0.296
  Itraconazole vs clotrimazole   0.96 (0.75, 1.23)   0.002               47.1%    0.738
  Ketoconazole vs clotrimazole   1.05 (0.90, 1.24)   --                  --       0.476
  Econazole vs clotrimazole      0.97 (0.76, 1.24)   0.032               38.4%    0.821
  Butoconazole vs clotrimazole   1.13 (1.03, 1.24)   0.987               0.0%     0.013
  Terconazole vs clotrimazole    1.06 (0.83, 1.34)   --                  --       0.634
  Ketoconazole vs miconazole     1.08 (0.92, 1.27)   0.066               44.7%    0.349
  Butoconazole vs miconazole     1.08 (1.01, 1.16)   0.844               0.0%     0.037
  Terconazole vs miconazole      1.04 (0.98, 1.12)   0.281               13.9%    0.210
  Terbinafine vs itraconazole    0.56 (0.22, 1.43)   --                  --       0.224
  Butoconazole vs econazole      1.19 (0.95, 1.51)   --                  --       0.137

###### 

Network meta-analysis comparisons

                 Placebo             Fluconazole         Clotrimazole        Miconazole          Itraconazole        Ketoconazole        Econazole           Butoconazole        Terbinafine         Terconazole
  -------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  Placebo        1                   0.04 (0.02, 0.07)   0.06 (0.03, 0.12)   0.09 (0.05, 0.16)   0.07 (0.03, 0.15)   0.08 (0.04, 0.16)   0.07 (0.03, 0.19)   0.04 (0.02, 0.09)   0.19 (0.03, 0.58)   0.06 (0.02, 0.13)
  Fluconazole    26.0 (14.0, 50.0)   1                   1.50 (1.1, 2.20)    2.20 (1.30, 3.90)   1.80 (0.99, 3.30)   2.00 (1.00, 4.10)   1.90 (0.84, 4.20)   1.00 (0.54, 1.90)   4.90 (0.85, 32.0)   1.40 (0.65, 3.10)
  Clotrimazole   17.0 (8.70, 34.0)   0.66 (0.45, 0.95)   1                   1.50 (0.80, 2.70)   1.20 (0.65, 2.20)   1.30 (0.64, 2.80)   1.20 (0.56, 2.70)   0.68 (0.35, 1.30)   3.30 (0.55, 22.0)   0.95 (0.41, 2.10)
  Miconazole     12.0 (6.30, 22.0)   0.45 (0.26, 0.78)   0.68 (0.37, 1.20)   1                   0.79 (0.38, 1.80)   0.90 (0.44, 1.90)   0.84 (0.33, 2.10)   0.47 (0.24, 0.87)   2.20 (0.36, 15.0)   0.65 (0.31, 1.30)
  Itraconazole   14.0 (6.40, 32.0)   0.56 (0.30, 1.00)   0.85 (0.46, 1.50)   1.30 (0.57, 2.70)   1                   1.10 (0.47, 2.70)   1.10 (0.39, 2.70)   0.58 (0.24, 1.30)   2.80 (0.48, 18.0)   0.81 (0.30, 2.10)
  Ketoconazole   13.0 (6.10, 27.0)   0.50 (0.24, 1.00)   0.76 (0.36, 1.60)   1.10 (0.53, 2.30)   0.88 (0.37, 2.20)   1                   0.94 (0.33, 2.60)   0.52 (0.21, 1.20)   2.50 (0.38, 18.0)   0.72 (0.27, 1.80)
  Econazole      14.0 (5.10, 38.0)   0.53 (0.24, 1.20)   0.80 (0.36, 1.80)   1.20 (0.47, 3.00)   0.94 (0.37, 2.50)   1.10 (0.38, 3.00)   1                   0.55 (0.22, 1.40)   2.60 (0.38, 20.0)   0.77 (0.26, 2.20)
  Butoconazole   25.0 (12.0, 56.0)   0.96 (0.51, 1.80)   1.50 (0.77, 2.80)   2.10 (1.10, 4.10)   1.70 (0.76, 4.40)   1.90 (0.83, 4.70)   1.80 (0.73, 4.60)   1                   4.70 (0.74, 34.0)   1.40 (0.57, 3.40)
  Terbinafine    5.20 (1.70, 35.0)   0.20 (0.03, 1.20)   0.31 (0.05, 1.80)   0.45 (0.06, 2.80)   0.35 (0.05, 2.10)   0.40 (0.06, 2.70)   0.38 (0.05, 2.60)   0.21 (0.03, 1.30)   1                   0.29 (0.04, 2.00)
  Terconazole    18.0 (7.80, 43.0)   0.69 (0.32, 1.50)   1.10 (0.47, 2.40)   1.50 (0.75, 3.20)   1.20 (0.49, 3.30)   1.40 (0.55, 3.70)   1.30 (0.45, 3.90)   0.72 (0.29, 1.80)   3.40 (0.51, 26.0)   1

[^1]: These authors contributed equally to this work
